AUTHORS

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at http://www.bretjenseninvests.com. Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.

Email Bret Jensen

Recent Articles By The Author

These 2 Biotech Stocks Are No Longer 'Off the Radar'

Bret Jensen Apr 17, 2019 9:14 AM EDT

Few parts of the market have more volatility than the small caps in this sector.

Discovery Financial Is a Solid, Low-Beta Value Play

Bret Jensen Apr 15, 2019 10:15 AM EDT

A look at the financials as earnings season kicks into high gear.

These 3 Biotech Stocks Are Moving Closer to Profitability

Bret Jensen Apr 12, 2019 8:41 AM EDT

Here are updates on small biotech/biopharma names I have profiled before.

You Don't Have to Swing for the Fences With Every Investment in Small Caps

Bret Jensen Apr 10, 2019 9:09 AM EDT

The way I do that is by using buy-write option strategies.

Stepping Carefully Into the Second Quarter

Bret Jensen Apr 8, 2019 10:00 AM EDT

The potential for so-so earnings results among the S&P 500 and an initial lackluster response to IPOs could cause investors to pause a bit after a strong first three months of 2019.

Construction Stocks Positioned to Claw Back 2018 Declines

Bret Jensen Apr 5, 2019 9:52 AM EDT

Construction spending hasn't sent ambivalent signals in 2019.

3 Promising Small Biotech Stocks to Watch

Bret Jensen Apr 3, 2019 9:31 AM EDT

I think there is still upside left in a variety of smaller names especially if M&A activity picks up across the industry.

Keep Your Eye on the Oncology Sector Among Biotech Stocks

Bret Jensen Apr 1, 2019 10:00 AM EDT

The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.

Until Next Time

Bret Jensen Mar 29, 2019 4:05 PM EDT

Nice to fill in for Doug Kass during a nice rally to close out a stellar first quarter for investors. The Dow posted its fourth up trading session in five this week. White House advisor Larry Kudlow comments today that the Fed Reserve should cut rat...

Seattle Genetics Struggles as Other Biotech Stocks Rise

Bret Jensen Mar 29, 2019 2:43 PM EDT

Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...

Email

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.